Velmetia, 1000 mg+50 mg 56 pcs.

Pharmacotherapeutic group:
Hypoglycemic agent for oral administration combined (dipeptidyl peptidase-4-inhibitor + biguanide)
ATC:
A.10.B.D Combination of biguanides and sulfonylurea derivatives
A.10.B.D.07 Metformin and sitagliptin

Pharmacodynamics:
The drug Velmetia® is a combination of two hypoglycemic drugs with complementary (complementary) mechanism of action, designed to improve glycemic control in patients with type 2 diabetes: sitagliptin. an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), and metformin, a representative of the class of biguanides.

Indications

Active ingredient

Composition

Active ingredients:

sitagliptin phosphate monohydrate 64.25 mg (equivalent to 50 mg sitagliptin) and metformin hydrochloride 1000 mg.

Auxiliary substances:

Microcrystalline cellulose 112.3 mg,

Povidone K-29/32 91.00 mg,

sodium stearyl fumarate 26.00 mg,

sodium lauryl sulfate 6.500 mg.

The tablet sheath Opadray® II red, 85F15464 (32.50 mg) contains:

Polyvinyl alcohol 48.300%,

Titanium dioxide (E 171) 6.000%,

Macrogol 3350 (polyethylene glycol) 24.380%,

talc 17.870%,

iron oxide black (E 172) 0.150%,

iron oxide red (E 172) 3.300%.

How to take, the dosage

Contraindications

Side effects

Similarities